TROGLITAZONE

Troglitazone decreases insulin resistance (improves insulin sensitivit y), which results in reduced plasma glucose and insulin levels in pati ents with non-insulin-dependent diabetes mellitus (NIDDM). Risk factor s for cardiovascular disease such as elevated proinsulin and triglycer ide levels are also reduced by troglitazone. In clinical trials, trogl itazone 200 to 800 mg daily (alone or in combination with other oral a ntidiabetic agents or insulin) reduced plasma or serum glucose levels and glycosylated haemoglobin compared with both baseline and placebo i n patients with NIDDM refractory to other oral antidiabetic agents (us ually suphonylureas). Troglitazone was generally well tolerated in cli nical trials. In patients in the US, the incidence of adverse events i n troglitazone recipients was similar to that in placebo recipients.